

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Dorzolamide Hydrochloride Ophthalmic Solution USP

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Dorzolamide Hydrochloride USP 22.3 mg

Eq. to Dorzolamide USP 20mg

Benzalkonium Chloride USP 0.0075% w/v

(As preservative)

3. PHARMACEUTICAL FORM

Ophthalmic Solution

A clear colourless ophthalmic solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Dorzolamide' is indicated:

- as adjunctive therapy to beta-blockers,
- as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated,

In the treatment of elevated intra-ocular pressure in:

- ocular hypertension,
- open angle glaucoma,
- pseudoexfoliative glaucoma

4.2 POSOLOGY AND METHOD OF ADMINISTRATION

Posology

When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.

When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), two times daily.

When substituting dorzolamide for another ophthalmic anti-glaucoma agent, discontinue the other agent after proper dosing on one day, and start dorzolamide on the next day.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

The dosage and duration of the treatment should be as recommended by the doctor.

If one dose is missed, treatment should continue with the next dose as normal.

Patients should be instructed to wash their hands before use and avoid allowing the tip of the bottle to come into contact with the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should be informed of the correct handling of the containers.

Paediatric population

Limited clinical data in paediatric patients with administration of dorzolamide three times a day are available.

1. Method of administration First wash your hands.
2. Avoid touching the eye (or any other surface) with the tip of the bottle.
3. If you wear soft contact lenses, they should be removed before using the eye drops and wait at least 15 minutes before reinserting.
4. These drops are supplied in a plastic bottle with an insert cap assembly, with a tamper proof dust cover. When using the bottle for the first time, snap off the dust cover by turning it clockwise to break the seal.

5. Unscrew the inner cap.
6. Tilt your head back and look at the ceiling.
7. Pull the lower eyelid gently downwards to form a pocket between your eyelid and your eye.
8. Hold the bottle upside down above the eye and gently squeeze the bottle to release a drop into your eye. **DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP.**
9. Keep the affected eye closed and press your fingertip against the inside corner of the closed eye, and hold for 2 minute.
10. Repeat for the other eye if instructed to do so by your doctor.
11. Recap the bottle after every use, tighten the inner cap on the nozzle.

4.3 CONTRAINDICATIONS:

Hypersensitivity to the active substance or to any of the excipients listed.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.

The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide has not been studied in patients with acute angle-closure glaucoma.

Dorzolamide contains a sulphonamido group, which also occurs in sulphonamides and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulphonamides may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acid-base disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently. Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.

If allergic reactions (e.g., conjunctivitis and eye-lid reactions) are observed, discontinuation of treatment should be considered.

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide. The concomitant administration of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.

Corneal oedemas and irreversible corneal decompensations have been reported in patients with pre-existing chronic corneal defects and/or a history of intra-ocular surgery while using Dorzolamide 20mg/ml Eye Drops Solution. Topical dorzolamide should be used with caution in such patients.

Choroidal detachment concomitant with ocular hypotony have been reported after filtration procedures with administration of aqueous suppressant therapies.

Dorzolamide 20mg/ml Eye Drops Solution contains the preservative benzalkonium chloride.. Use of benzalkonium chloride with soft contact lenses should be avoided. Contact lenses should be removed prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.

Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.

Paediatric population

Dorzolamide has not been studied in patients less than 36 weeks gestational age and less than 1 week of age. Patients with significant renal tubular immaturity should only receive dorzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis.

4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Specific drug interaction studies have not been performed with dorzolamide.

In clinical studies, dorzolamide was used concomitantly with the following medications without evidence of adverse interactions: timolol ophthalmic solution, betaxolol ophthalmic solution and

systemic medications, including ACE-inhibitors, calcium-channel blockers, diuretics, non-steroidal anti-inflammatory drugs including aspirin, and hormones (e.g. oestrogen, insulin, thyroxine). Association between dorzolamide and miotics and adrenergic agonists has not been fully evaluated during glaucoma therapy

4.6 FERTILITY, PREGNANCY AND LACTATION

Pregnancy

Dorzolamide should not be used during pregnancy. There are no or limited amount of data from the use of dorzolamide in pregnant women. In rabbits, dorzolamide produced teratogenic effects at maternotoxic doses.

Breast-feeding

It is unknown whether dorzolamide/metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of dorzolamide/metabolites in milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Dorzolamide therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. A risk to the newborns/infants cannot be excluded.

Fertility

Animal data do not suggest an effect of treatment with dorzolamide on male and female fertility. Human data are lacking.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive and use machines have been performed. Possible side effects such as dizziness and visual disturbances may affect the ability to drive and use machines.

4.8 UNDESIRABLE EFFECTS

The following adverse reactions have been reported either during clinical trials or during post-marketing experience with dorzolamide:

Very common: ($\geq 1/10$), Common: ($\geq 1/100$ to $<1/10$), Uncommon: ($\geq 1/1,000$ to $<1/100$), Rare: ($\geq 1/10,000$ to $<1/1,000$), Not known: (cannot be estimated from the available data]

Nervous system disorders:

Common: headache

Rare: dizziness, paraesthesia

Cardiac disorders:

Not known: Palpitations

Eye disorders:

Very common: burning and stinging

Common: superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, eye itching, eyelid irritation, blurred vision

Uncommon: iridocyclitis

Rare: irritation including redness, pain, eyelid crusting, transient myopia (which resolved upon discontinuation of therapy), corneal oedema, ocular hypotony, choroidal detachment following filtration surgery

Not known: foreign body sensation in eye

Respiratory, thoracic, and mediastinal disorders:

Rare: epistaxis

Not known: dyspnoea

Gastrointestinal disorders:

Common: nausea, bitter taste

Rare: throat irritation, dry mouth

Skin and subcutaneous tissue disorders:

Rare: contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis

Renal and urinary disorders:

Rare: urolithiasis

General disorders and administration site conditions:

Common: asthenia/fatigue

Rare: hypersensitivity: signs and symptoms of local reactions (palpebral reactions) and systemic allergic reactions including angioedema, urticaria and pruritus, rash, shortness of breath, rarely bronchospasm

Investigations:

Dorzolamide was not associated with clinically meaningful electrolyte disturbances.

4.9 OVERDOSE

Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride.

Symptoms

The following have been reported with oral ingestion: somnolence; topical application: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.

Treatment

Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

5. PHARMACOLOGICAL PROPERTIES**5.1 PHARMACODYNAMIC PROPERTIES**

Pharmacotherapeutic group: Antiglaucoma preparations and miotics, Carbonic Anhydrase Inhibitors, dorzolamide,

ATC code: S01EC03

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion. The result is a reduction in intra-ocular pressure (IOP).

Dorzolamide 20mg/ml Eye Drops Solution contains dorzolamide hydrochloride, a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma. Elevated intra-ocular pressure is a major risk factor in the pathogenesis of optic nerve damage and visual-field loss. Dorzolamide does not cause pupillary constriction and reduces intra-ocular pressure without side effects such as night blindness, accommodative spasm. Dorzolamide has minimal or no effect on pulse rate or blood pressure.

Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. Studies have shown that when dorzolamide is added to a topical beta-blocker, additional reduction in IOP is observed; this finding is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.

Clinical efficacy and safety

Adult patients

In patients with glaucoma or ocular hypertension, the efficacy of dorzolamide given t.i.d. as monotherapy (baseline IOP \geq 23 mmHg) or given b.i.d. as adjunctive therapy while receiving ophthalmic beta-blockers (baseline IOP \geq 22 mmHg) was demonstrated in large-scale clinical studies of up to one-year duration. The IOP-lowering effect of dorzolamide as monotherapy and as adjunctive therapy was demonstrated throughout the day and this effect was maintained during long-term administration. Efficacy during long-term monotherapy was similar to betaxolol and slightly less than timolol. When used as adjunctive therapy to ophthalmic beta-blockers, dorzolamide demonstrated additional IOP lowering similar to pilocarpine 2% q.i.d.

Paediatric population

A 3-month, double-masked, active-treatment controlled, multicentre study was undertaken in 184 (122 for dorzolamide) paediatric patients from 1 week of age to <6 years of age with glaucoma or elevated intraocular pressure (baseline IOP \geq 22 mmHg) to assess the safety of Dorzolamide 20mg/ml Eye Drops Solution when administered topically t.i.d. (three times a day). Approximately half the patients in both treatment groups were diagnosed with congenital glaucoma; other common aetiologies were Sturge Weber syndrome, iridocorneal mesenchymal dysgenesis, aphakic patients. The distribution by age and treatments in the monotherapy phase was as follows:

	Dorzolamide 2%	Timolol
Age cohort < 2 years	N=56 Age range: 1 to 23 months	Timolol GS 0.25% N=27 Age range: 0.25 to 22 months

Age cohort ≥ 2 - < 6 years	N=66 Age range: 2 to 6 years	Timolol 0.50% N=35 Age range: 2 to 6 years
-----------------------------------	---------------------------------	--------------------------------------------

Across both age cohorts approximately 70 patients received treatment for at least 61 days and approximately 50 patients received 81-100 days of treatment.

If IOP was inadequately controlled on dorzolamide or timolol gel-forming solution monotherapy, a change was made to open-label therapy according to the following: 30 patients < 2 years were switched to concomitant therapy with timolol gel-forming solution 0.25% daily and dorzolamide 2% t.i.d.; 30 patients ≥ 2 years were switched to 2% dorzolamide/0.5% timolol fixed combination b.i.d (twice a day). Overall, this study did not reveal additional safety concerns in paediatric patients: approximately 26% (20% in dorzolamide monotherapy) of paediatric patients were observed to experience drug related adverse affects, the majority of which were local, non-serious ocular effects such as ocular burning and stinging, injection and eye pain. A small percentage $< 4\%$ was observed to have corneal oedema or haze. Local reactions appeared similar in frequency to comparator. In post marketing data, metabolic acidosis in the very young particularly with renal immaturity/impairment has been reported.

Efficacy results in paediatric patients suggest that the mean IOP decrease observed in the dorzolamide group was comparable to the mean IOP decrease observed in the timolol group even if a slight numeric advantage was observed for timolol.

Longer-term efficacy studies (> 12 weeks) are not available.

5.2 PHARMACOKINETIC PROPERTIES

Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.

When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, active substance and metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free active substance in plasma are maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II less potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs non linearly, resulting in a rapid decline of active substance concentration initially, followed by a slower elimination phase with a half-life of about four months.

When dorzolamide was given orally to simulate the maximum systemic exposure after long-term topical ocular administration, steady state was reached within 13 weeks. At steady state, there was virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic, topical administration of dorzolamide. However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition, and no clinically significant systemic side effects were directly attributable to this finding.

5.3 PRECLINICAL SAFETY DATA

Not Known

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzalkonium chloride, Hypromellose, Sodium Citrate, Mannitol, Sodium hydroxide/hydrochloric acid, Water for Injection.

6.2 Incompatibilities

Not known

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Store below 30°C. Protect from light.

Keep out of reach of children.

6.5 Nature and contents of container and special equipment for use, administration or implantation

5 ML LDPE Bottle

6.6 Special precautions for disposal and other handling

None.

7. MARKETING AUTHORISATION HOLDER

Ciron Drugs & Pharmaceuticals Pvt. Ltd.

C- 1101 /1102, Lotus Corporate Park, Graham Firth Steel Compound,

Jay Coach Junction, Western Express Highway, Goregaon (East)

Mumbai- 400 063, India.

8. MARKETING AUTHORISATION NUMBER(S)

CIRON/IND/609

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation : 15.05.2019

10. DATE OF REVISION OF THE TEXT

14/09/2023

11. Reference

<https://www.medicines.org.uk/emc/product/3320/smpc#gref>